Berezin, A.A.; Obradovic, Z.; Fushtey, I.M.; Berezina, T.A.; Novikov, E.V.; Schmidbauer, L.; Lichtenauer, M.; Berezin, A.E.
The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure. Biomedicines 2023, 11, 457.
https://doi.org/10.3390/biomedicines11020457
AMA Style
Berezin AA, Obradovic Z, Fushtey IM, Berezina TA, Novikov EV, Schmidbauer L, Lichtenauer M, Berezin AE.
The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure. Biomedicines. 2023; 11(2):457.
https://doi.org/10.3390/biomedicines11020457
Chicago/Turabian Style
Berezin, Alexander A., Zeljko Obradovic, Ivan M. Fushtey, Tetiana A. Berezina, Evgen V. Novikov, Lukas Schmidbauer, Michael Lichtenauer, and Alexander E. Berezin.
2023. "The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure" Biomedicines 11, no. 2: 457.
https://doi.org/10.3390/biomedicines11020457
APA Style
Berezin, A. A., Obradovic, Z., Fushtey, I. M., Berezina, T. A., Novikov, E. V., Schmidbauer, L., Lichtenauer, M., & Berezin, A. E.
(2023). The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure. Biomedicines, 11(2), 457.
https://doi.org/10.3390/biomedicines11020457